Outcome Capital - Strategic Life Sciences Investment Banking

Creating outcomes like no other. Maximizing your company’s value…

Unique Insights

In-Depth Industry Experience & Networks

Personal Commitment to Clients

Exceptional Record of Success

Community

About Outcome Life Sciences Pulse

We are driven to create value for our clients to secure the best possible outcome

The added value Outcome Capital was responsible for was 10 times greater than the value we invested in their services. Our only regret was in not bringing them on sooner.

John D Green, MD CEO, Advanced Uro-Solutions
An Outcome professional served as lead banker in the sale of Annese & Associates. His knowledge of our industry, extensive contacts within it, and attention to all facets of the transaction proved invaluable. His care and commitment to the Annese shareholders, board, myself and by extension to all of our employees was simply outstanding.

Ray Apy CEO, Annese & Associates
The diversity of backgrounds enables Outcome to offer deep understanding and unique insights

The Outcome team got fully up to speed with all aspects of our technology and business, and could pitch our company’s story, and value proposition, as well as anyone. They researched a full list of potential acquirers in order to target those with high potential, and articulate the true value proposition for each target in very clear terms.

Victor Esch, PhD President & CEO, DNAe
Outcome Capital’s knowledge and expertise were crucial in bringing this transaction to fruition. Outcome advised us on both the acquisition and the financing and exceeded all our expectations.

Rolf Purzer CEO, ATPCO
In-depth Industry Knowledge & Networks

I was impressed by Outcome Capital’s thoughtful M&A strategy and process, which stemmed from their ability to capture the complexities of Beryllium’s scientific and business value propositions.

Johan Pontin CEO, Beryllium Discovery
The Outcome Capital team was a committed and flexible partner that proved critical to a successful acquisition.

Mahfuz Ahmed CEO, DISYS
Passionately working for our clients' success

I have worked with Outcome Capital on multiple, complex transactions. They bring strategic insights and operational experience to the table like no other investment bankers I have ever worked with.

Lisa Dunlea CEO, XableCath
I knew Outcome by reputation, and they were the only group I felt comfortable engaging with and trusting with this deal. What they provided exceeded my expectations not only in value, but also in their conduct and earnestness. It was a pleasure doing business with Outcome Capital.

Andrew Ferrara Chairman, Boston Healthcare Associates
I thank the Outcome team for driving the Verrix acquisition to completion, for protecting our interests and for an excellent job in navigating the bumps along the way. The Outcome team ran a solid competitive process that caused the market to speak toward a transaction for the benefit of both buyer and seller.

Sami El-Saden Chairman and CEO, Verrix

Transactions

Has sold its business to

Received an equity investment from

Has sold its business to

Has been acquired by

Has been acquired by an Undisclosed Family Office

Capital Raise

Has sold its business to

Has Sold its Energy Management Business to

Has Acquired

Has Received an Investment From

Has Acquired

Has Purchased

Acquisition Funding Provided By

Has Sold Its Business To

Has Sold Its Smart Grid Solutions Business To

Has Issued 5,000,000 Shares of Series A Preferred Stock

Has Sold Its Business To

$15,000,000

View More Transactions

News November 12, 2021

Outcome Capital Announces Getinge Has Acquired Verrix

November 12, 2021 10:48 AM Eastern Standard Time BOSTON–(BUSINESS WIRE)–Outcome Capital, a specialized life sciences and healthcare advisory and investment banking firm, today announced that Getinge has acquired Verrix LLC. Outcome Capital served as the exclusive strategic and financial advisor to Verrix. “There is a growing demand for biological indicators from healthcare institutions around the […]

Outcome Capital Congratulates Dr. Ellen Baron for the AbCellera Acquisition of TetraGenetics

September 13, 2021 Vancouver, British Columbia & Boston, MA. AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced it has acquired TetraGenetics, Inc. (TetraGenetics), a biotechnology company with a proprietary platform for generating recombinant human ion channels and other transmembrane proteins, in an all-cash transaction that includes […]

Outcome Capital Life Sciences Pulse

Outcome Capital Life Science Market Pulse November 2021 Click to view our LifeSciences Pulse Newsletter

Download

Contact Us for More Information

Would you like to learn more about working with Outcome Capital or discuss your specific needs?

Life Sciences

Healthcare

View Our Monthly Newsletter

Unique Insights

In-Depth Industry Experience & Networks

Personal Commitment to Clients

Exceptional Record of Success

Community

We are driven to create value for our clients to secure the best possible outcome

John D Green, MD CEO, Advanced Uro-Solutions

Ray Apy CEO, Annese & Associates

The diversity of backgrounds enables Outcome to offer deep understanding and unique insights

Victor Esch, PhD President & CEO, DNAe

Rolf Purzer CEO, ATPCO

In-depth Industry Knowledge & Networks

Johan Pontin CEO, Beryllium Discovery

Mahfuz Ahmed CEO, DISYS

Passionately working for our clients' success

Lisa Dunlea CEO, XableCath

Andrew Ferrara Chairman, Boston Healthcare Associates

Sami El-Saden Chairman and CEO, Verrix

News November 12, 2021

Outcome Capital Announces Getinge Has Acquired Verrix

News October 05, 2021

Outcome Capital Congratulates Dr. Ellen Baron for the AbCellera Acquisition of TetraGenetics

Life Sciences Pulse November 2021

Outcome Capital Life Sciences Pulse